JP2023542297A - 異種プライムブーストワクチン - Google Patents

異種プライムブーストワクチン Download PDF

Info

Publication number: JP2023542297A
Authority: JP; Japan
Prior art keywords: seq; component; amino acid; acid sequence; epitopes
Prior art date: 2020-09-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2023516483A

Other languages

English (en)

Japanese (ja)

Inventor

ヴォルマン，グイド

ダス，クリシュナ

デロアジ，マディハ

ベルヌー，エロディ

エルバース，クヌート

Original Assignee

ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-09-14

Filing date

2021-09-14

Publication date

2023-10-06

2021-09-14 Application filed by ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング filed Critical ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング

2023-10-06 Publication of JP2023542297A publication Critical patent/JP2023542297A/ja

Status Pending legal-status Critical Current

Links

229940023867 prime-boost vaccine Drugs 0.000 title claims description 8
206010028980 Neoplasm Diseases 0.000 claims abstract description 319
230000000890 antigenic effect Effects 0.000 claims abstract description 290
229960005486 vaccine Drugs 0.000 claims abstract description 242
241000711975 Vesicular stomatitis virus Species 0.000 claims abstract description 132
201000011510 cancer Diseases 0.000 claims abstract description 82
230000000174 oncolytic effect Effects 0.000 claims abstract description 68
239000000556 agonist Substances 0.000 claims abstract description 59
108010051109 Cell-Penetrating Peptides Proteins 0.000 claims abstract description 46
102000020313 Cell-Penetrating Peptides Human genes 0.000 claims abstract description 45
238000011282 treatment Methods 0.000 claims abstract description 27
125000003275 alpha amino acid group Chemical group 0.000 claims description 306
239000000427 antigen Substances 0.000 claims description 272
108091007433 antigens Proteins 0.000 claims description 270
102000036639 antigens Human genes 0.000 claims description 270
108090000765 processed proteins & peptides Proteins 0.000 claims description 221
150000001413 amino acids Chemical class 0.000 claims description 155
108090000623 proteins and genes Proteins 0.000 claims description 143
239000012634 fragment Substances 0.000 claims description 127
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 111
108010002687 Survivin Proteins 0.000 claims description 108
-1 βhCG Proteins 0.000 claims description 93
102000002689 Toll-like receptor Human genes 0.000 claims description 92
108020000411 Toll-like receptor Proteins 0.000 claims description 92
102100022144 Achaete-scute homolog 2 Human genes 0.000 claims description 90
102100034256 Mucin-1 Human genes 0.000 claims description 87
108010008707 Mucin-1 Proteins 0.000 claims description 86
108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 83
102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 83
102000004196 processed proteins & peptides Human genes 0.000 claims description 82
102000004169 proteins and genes Human genes 0.000 claims description 80
102000003886 Glycoproteins Human genes 0.000 claims description 69
108090000288 Glycoproteins Proteins 0.000 claims description 69
101150105104 Kras gene Proteins 0.000 claims description 67
229940122985 Peptide agonist Drugs 0.000 claims description 60
229920001184 polypeptide Polymers 0.000 claims description 57
SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 51
102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 51
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 50
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 50
101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 47
102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 46
102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims description 45
101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims description 45
238000000034 method Methods 0.000 claims description 45
102100038916 Caspase-5 Human genes 0.000 claims description 44
102100037920 Insulin-like growth factor 2 mRNA-binding protein 3 Human genes 0.000 claims description 44
101100452137 Homo sapiens IGF2BP3 gene Proteins 0.000 claims description 43
108091008605 VEGF receptors Proteins 0.000 claims description 43
101000801539 Homo sapiens Mitochondrial import receptor subunit TOM34 Proteins 0.000 claims description 42
102100033583 Mitochondrial import receptor subunit TOM34 Human genes 0.000 claims description 42
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 42
108010046722 Thrombospondin 1 Proteins 0.000 claims description 38
102100036034 Thrombospondin-1 Human genes 0.000 claims description 38
206010009944 Colon cancer Diseases 0.000 claims description 36
241000700605 Viruses Species 0.000 claims description 35
238000002255 vaccination Methods 0.000 claims description 34
101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 32
241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 32
102100024333 Toll-like receptor 2 Human genes 0.000 claims description 32
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 31
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 28
210000001744 T-lymphocyte Anatomy 0.000 claims description 28
101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 27
102100039360 Toll-like receptor 4 Human genes 0.000 claims description 27
102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 22
102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 21
101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 21
108010089430 Phosphoproteins Proteins 0.000 claims description 19
102000007982 Phosphoproteins Human genes 0.000 claims description 19
108060003393 Granulin Proteins 0.000 claims description 18
229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 17
102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 17
108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 17
108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 17
108060006580 PRAME Proteins 0.000 claims description 14
102000036673 PRAME Human genes 0.000 claims description 14
241000711970 Vesiculovirus Species 0.000 claims description 14
102100037907 High mobility group protein B1 Human genes 0.000 claims description 11
102000007999 Nuclear Proteins Human genes 0.000 claims description 11
108010089610 Nuclear Proteins Proteins 0.000 claims description 11
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
208000015634 Rectal Neoplasms Diseases 0.000 claims description 11
241000711959 Vesicular stomatitis New Jersey virus Species 0.000 claims description 11
208000029742 colonic neoplasm Diseases 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 11
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 11
201000002528 pancreatic cancer Diseases 0.000 claims description 11
208000008443 pancreatic carcinoma Diseases 0.000 claims description 11
206010038038 rectal cancer Diseases 0.000 claims description 10
201000001275 rectum cancer Diseases 0.000 claims description 10
206010006187 Breast cancer Diseases 0.000 claims description 9
208000026310 Breast neoplasm Diseases 0.000 claims description 9
102000011931 Nucleoproteins Human genes 0.000 claims description 9
108010061100 Nucleoproteins Proteins 0.000 claims description 9
241000711973 Vesicular stomatitis Indiana virus Species 0.000 claims description 9
239000002246 antineoplastic agent Substances 0.000 claims description 9
229940079593 drug Drugs 0.000 claims description 9
206010052358 Colorectal cancer metastatic Diseases 0.000 claims description 8
208000002699 Digestive System Neoplasms Diseases 0.000 claims description 8
101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 8
102100039357 Toll-like receptor 5 Human genes 0.000 claims description 8
208000002458 carcinoid tumor Diseases 0.000 claims description 8
229940127089 cytotoxic agent Drugs 0.000 claims description 8
230000002519 immonomodulatory effect Effects 0.000 claims description 8
239000002955 immunomodulating agent Substances 0.000 claims description 8
230000001965 increasing effect Effects 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 8
102000004149 Annexin A2 Human genes 0.000 claims description 7
108090000668 Annexin A2 Proteins 0.000 claims description 7
206010004593 Bile duct cancer Diseases 0.000 claims description 7
208000021780 appendiceal neoplasm Diseases 0.000 claims description 6
208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
108010074708 B7-H1 Antigen Proteins 0.000 claims description 5
241000208654 Dandenong virus Species 0.000 claims description 5
208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 5
208000009849 Female Genital Neoplasms Diseases 0.000 claims description 5
241000712897 Mopeia mammarenavirus Species 0.000 claims description 5
208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
208000026900 bile duct neoplasm Diseases 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
201000011523 endocrine gland cancer Diseases 0.000 claims description 5
206010017758 gastric cancer Diseases 0.000 claims description 5
230000002496 gastric effect Effects 0.000 claims description 5
208000014829 head and neck neoplasm Diseases 0.000 claims description 5
230000037361 pathway Effects 0.000 claims description 5
230000000241 respiratory effect Effects 0.000 claims description 5
201000011549 stomach cancer Diseases 0.000 claims description 5
208000003265 stomatitis Diseases 0.000 claims description 5
241000712891 Arenavirus Species 0.000 claims description 4
206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims description 4
241000711969 Chandipura virus Species 0.000 claims description 4
241000501789 Cocal virus Species 0.000 claims description 4
208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 4
101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 claims description 4
241001109688 Isfahan virus Species 0.000 claims description 4
241001372913 Maraba virus Species 0.000 claims description 4
206010029098 Neoplasm skin Diseases 0.000 claims description 4
208000000453 Skin Neoplasms Diseases 0.000 claims description 4
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 4
229960003852 atezolizumab Drugs 0.000 claims description 4
229950002916 avelumab Drugs 0.000 claims description 4
229940121420 cemiplimab Drugs 0.000 claims description 4
229950009791 durvalumab Drugs 0.000 claims description 4
201000010175 gallbladder cancer Diseases 0.000 claims description 4
201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 4
201000005787 hematologic cancer Diseases 0.000 claims description 4
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
230000003053 immunization Effects 0.000 claims description 4
238000002649 immunization Methods 0.000 claims description 4
230000008595 infiltration Effects 0.000 claims description 4
238000001764 infiltration Methods 0.000 claims description 4
229960003301 nivolumab Drugs 0.000 claims description 4
229960002621 pembrolizumab Drugs 0.000 claims description 4
229950010773 pidilizumab Drugs 0.000 claims description 4
241001587975 recombinant Vesiculovirus Species 0.000 claims description 4
206010061424 Anal cancer Diseases 0.000 claims description 3
208000007860 Anus Neoplasms Diseases 0.000 claims description 3
206010007275 Carcinoid tumour Diseases 0.000 claims description 3
241000711965 Piry virus Species 0.000 claims description 3
102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
201000011165 anus cancer Diseases 0.000 claims description 3
210000004185 liver Anatomy 0.000 claims description 3
230000010076 replication Effects 0.000 claims description 3
210000000115 thoracic cavity Anatomy 0.000 claims description 3
208000005925 vesicular stomatitis Diseases 0.000 claims description 3
230000001413 cellular effect Effects 0.000 claims description 2
208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 2
206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 21
101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 21
101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 21
102000000763 Survivin Human genes 0.000 claims 17
101000901109 Homo sapiens Achaete-scute homolog 2 Proteins 0.000 claims 14
102000008096 B7-H1 Antigen Human genes 0.000 claims 2
201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims 2
208000025426 neoplasm of thorax Diseases 0.000 claims 2
201000003957 thoracic cancer Diseases 0.000 claims 2
206010008761 Choriomeningitis lymphocytic Diseases 0.000 claims 1
101000741072 Homo sapiens Caspase-5 Proteins 0.000 claims 1
210000004392 genitalia Anatomy 0.000 claims 1
238000009169 immunotherapy Methods 0.000 claims 1
208000001419 lymphocytic choriomeningitis Diseases 0.000 claims 1
238000012737 microarray-based gene expression Methods 0.000 claims 1
238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
229940022399 cancer vaccine Drugs 0.000 abstract description 5
238000009566 cancer vaccine Methods 0.000 abstract description 4
238000010586 diagram Methods 0.000 abstract description 4
235000001014 amino acid Nutrition 0.000 description 139
229940024606 amino acid Drugs 0.000 description 135
102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 91
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 90
101710165189 Achaete-scute homolog 2 Proteins 0.000 description 76
210000004027 cell Anatomy 0.000 description 67
235000018102 proteins Nutrition 0.000 description 64
101000992235 Homo sapiens UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit Proteins 0.000 description 51
102100031929 UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit Human genes 0.000 description 51
239000000562 conjugate Substances 0.000 description 46
108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 45
101710090333 Caspase-5 Proteins 0.000 description 43
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 43
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 42
229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 42
102000000440 Melanoma-associated antigen Human genes 0.000 description 40
108050008953 Melanoma-associated antigen Proteins 0.000 description 40
241000699670 Mus sp. Species 0.000 description 37
208000022361 Human papillomavirus infectious disease Diseases 0.000 description 19
239000002158 endotoxin Substances 0.000 description 17
229920006008 lipopolysaccharide Polymers 0.000 description 17
230000014509 gene expression Effects 0.000 description 16
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 15
210000004443 dendritic cell Anatomy 0.000 description 14
230000006870 function Effects 0.000 description 14
238000000684 flow cytometry Methods 0.000 description 13
108010040721 Flagellin Proteins 0.000 description 12
238000002513 implantation Methods 0.000 description 12
230000004614 tumor growth Effects 0.000 description 12
241000283070 Equus zebra Species 0.000 description 11
230000028993 immune response Effects 0.000 description 11
239000003446 ligand Substances 0.000 description 10
210000001165 lymph node Anatomy 0.000 description 10
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 9
108010028921 Lipopeptides Proteins 0.000 description 9
108700018351 Major Histocompatibility Complex Proteins 0.000 description 9
102000003735 Mesothelin Human genes 0.000 description 9
108090000015 Mesothelin Proteins 0.000 description 9
208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 9
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 9
230000001580 bacterial effect Effects 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
210000004681 ovum Anatomy 0.000 description 9
238000006467 substitution reaction Methods 0.000 description 9
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
208000022679 triple-negative breast carcinoma Diseases 0.000 description 9
210000004881 tumor cell Anatomy 0.000 description 9
239000013598 vector Substances 0.000 description 9
210000000612 antigen-presenting cell Anatomy 0.000 description 8
210000001072 colon Anatomy 0.000 description 8
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
230000035772 mutation Effects 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
108091054437 MHC class I family Proteins 0.000 description 7
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
102100022748 Wilms tumor protein Human genes 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
230000003834 intracellular effect Effects 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
210000004379 membrane Anatomy 0.000 description 7
239000012528 membrane Substances 0.000 description 7
230000004044 response Effects 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
102000011022 Chorionic Gonadotropin Human genes 0.000 description 6
108010062540 Chorionic Gonadotropin Proteins 0.000 description 6
108010067306 Fibronectins Proteins 0.000 description 6
102000016359 Fibronectins Human genes 0.000 description 6
102100030708 GTPase KRas Human genes 0.000 description 6
101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 6
241000701044 Human gammaherpesvirus 4 Species 0.000 description 6
230000024932 T cell mediated immunity Effects 0.000 description 6
102100027010 Toll-like receptor 1 Human genes 0.000 description 6
210000000170 cell membrane Anatomy 0.000 description 6
201000001441 melanoma Diseases 0.000 description 6
DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 6
210000000952 spleen Anatomy 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
102000001398 Granzyme Human genes 0.000 description 5
108060005986 Granzyme Proteins 0.000 description 5
101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 5
108090001030 Lipoproteins Proteins 0.000 description 5
102000004895 Lipoproteins Human genes 0.000 description 5
102000043129 MHC class I family Human genes 0.000 description 5
108091054438 MHC class II family Proteins 0.000 description 5
206010027476 Metastases Diseases 0.000 description 5
108010058846 Ovalbumin Proteins 0.000 description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
230000000259 anti-tumor effect Effects 0.000 description 5
229940084986 human chorionic gonadotropin Drugs 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
230000036039 immunity Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
229940092253 ovalbumin Drugs 0.000 description 5
210000005259 peripheral blood Anatomy 0.000 description 5
239000011886 peripheral blood Substances 0.000 description 5
230000037452 priming Effects 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
230000005945 translocation Effects 0.000 description 5
241000701161 unidentified adenovirus Species 0.000 description 5
108700031308 Antennapedia Homeodomain Proteins 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
206010052360 Colorectal adenocarcinoma Diseases 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
241000282412 Homo Species 0.000 description 4
101100232357 Homo sapiens IL13RA1 gene Proteins 0.000 description 4
101100232360 Homo sapiens IL13RA2 gene Proteins 0.000 description 4
208000007433 Lymphatic Metastasis Diseases 0.000 description 4
102000043131 MHC class II family Human genes 0.000 description 4
241000711931 Rhabdoviridae Species 0.000 description 4
108091008874 T cell receptors Proteins 0.000 description 4
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
102000040945 Transcription factor Human genes 0.000 description 4
108091023040 Transcription factor Proteins 0.000 description 4
230000003213 activating effect Effects 0.000 description 4
230000004913 activation Effects 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000012636 effector Substances 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000015654 memory Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
244000052769 pathogen Species 0.000 description 4
230000001717 pathogenic effect Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
102000008467 protein O-GlcNAc transferase activity proteins Human genes 0.000 description 4
210000001599 sigmoid colon Anatomy 0.000 description 4
230000011664 signaling Effects 0.000 description 4
238000010186 staining Methods 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
210000001550 testis Anatomy 0.000 description 4
238000010361 transduction Methods 0.000 description 4
230000026683 transduction Effects 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
108091007065 BIRCs Proteins 0.000 description 3
238000011740 C57BL/6 mouse Methods 0.000 description 3
108010076667 Caspases Proteins 0.000 description 3
102000011727 Caspases Human genes 0.000 description 3
150000008574 D-amino acids Chemical class 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 3
241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
241000341655 Human papillomavirus type 16 Species 0.000 description 3
102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 3
102000003816 Interleukin-13 Human genes 0.000 description 3
108090000176 Interleukin-13 Proteins 0.000 description 3
150000008575 L-amino acids Chemical class 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
208000018142 Leiomyosarcoma Diseases 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 3
101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 3
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 3
102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 3
239000013543 active substance Substances 0.000 description 3
208000009956 adenocarcinoma Diseases 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
210000004602 germ cell Anatomy 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
230000007774 longterm Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
244000005700 microbiome Species 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
229950006780 n-acetylglucosamine Drugs 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
210000001672 ovary Anatomy 0.000 description 3
239000000816 peptidomimetic Substances 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
230000004481 post-translational protein modification Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
108040002385 protein O-GlcNAc transferase activity proteins Proteins 0.000 description 3
210000000664 rectum Anatomy 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000008685 targeting Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000032258 transport Effects 0.000 description 3
238000011269 treatment regimen Methods 0.000 description 3
230000034512 ubiquitination Effects 0.000 description 3
238000010798 ubiquitination Methods 0.000 description 3
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
108091008875 B cell receptors Proteins 0.000 description 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
208000006478 Cecal Neoplasms Diseases 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
208000006332 Choriocarcinoma Diseases 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
101710200374 Crotamine Proteins 0.000 description 2
102000001301 EGF receptor Human genes 0.000 description 2
108060006698 EGF receptor Proteins 0.000 description 2
101150029707 ERBB2 gene Proteins 0.000 description 2
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
101710087998 Eumenine mastoparan-AF Proteins 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
241000233866 Fungi Species 0.000 description 2
108010015899 Glycopeptides Proteins 0.000 description 2
102000002068 Glycopeptides Human genes 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
108010075704 HLA-A Antigens Proteins 0.000 description 2
102000002812 Heat-Shock Proteins Human genes 0.000 description 2
108010004889 Heat-Shock Proteins Proteins 0.000 description 2
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 2
101001095088 Homo sapiens Melanoma antigen preferentially expressed in tumors Proteins 0.000 description 2
101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
241000701806 Human papillomavirus Species 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
102000009151 Luteinizing Hormone Human genes 0.000 description 2
108010073521 Luteinizing Hormone Proteins 0.000 description 2
208000007054 Medullary Carcinoma Diseases 0.000 description 2
102100037020 Melanoma antigen preferentially expressed in tumors Human genes 0.000 description 2
108010036176 Melitten Proteins 0.000 description 2
241000579048 Merkel cell polyomavirus Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
101000933115 Mus musculus Caspase-4 Proteins 0.000 description 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
102100025803 Progesterone receptor Human genes 0.000 description 2
101710149951 Protein Tat Proteins 0.000 description 2
201000010208 Seminoma Diseases 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
208000009125 Sigmoid Neoplasms Diseases 0.000 description 2
101710172711 Structural protein Proteins 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
102000011923 Thyrotropin Human genes 0.000 description 2
108010061174 Thyrotropin Proteins 0.000 description 2
102100024324 Toll-like receptor 3 Human genes 0.000 description 2
101710120037 Toxin CcdB Proteins 0.000 description 2
108700019146 Transgenes Proteins 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
108010003533 Viral Envelope Proteins Proteins 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
208000008383 Wilms tumor Diseases 0.000 description 2
229920000392 Zymosan Polymers 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000033289 adaptive immune response Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
230000030741 antigen processing and presentation Effects 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
210000001815 ascending colon Anatomy 0.000 description 2
201000010838 ascending colon cancer Diseases 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
108010081355 beta 2-Microglobulin Proteins 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
210000004534 cecum Anatomy 0.000 description 2
201000003959 cecum carcinoma Diseases 0.000 description 2
230000021164 cell adhesion Effects 0.000 description 2
230000004700 cellular uptake Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
208000022136 colorectal lymphoma Diseases 0.000 description 2
208000016496 colorectal squamous cell carcinoma Diseases 0.000 description 2
PEFQQQGFYPMQLH-WFQFKEFWSA-N crotamin Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CC(C)C)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3CSSC[C@H](NC(=O)[C@H](CC=4NC=NC=4)NC(=O)CNC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=4C=CC(O)=CC=4)CSSC[C@@H](C(=O)N[C@@H](CSSC2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C4=CC=CC=C4NC=2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=2C4=CC=CC=C4NC=2)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N1)=O)[C@@H](C)CC)C1=CC=CC=C1 PEFQQQGFYPMQLH-WFQFKEFWSA-N 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
210000001731 descending colon Anatomy 0.000 description 2
201000003823 descending colon cancer Diseases 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000013020 embryo development Effects 0.000 description 2
230000012202 endocytosis Effects 0.000 description 2
102000015694 estrogen receptors Human genes 0.000 description 2
108010038795 estrogen receptors Proteins 0.000 description 2
230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
238000013401 experimental design Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
208000005017 glioblastoma Diseases 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
230000028996 humoral immune response Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
210000003767 ileocecal valve Anatomy 0.000 description 2
230000006054 immunological memory Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000015788 innate immune response Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
210000005061 intracellular organelle Anatomy 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
210000004901 leucine-rich repeat Anatomy 0.000 description 2
201000007270 liver cancer Diseases 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
229940040129 luteinizing hormone Drugs 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
238000009126 molecular therapy Methods 0.000 description 2
201000010879 mucinous adenocarcinoma Diseases 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
230000035699 permeability Effects 0.000 description 2
238000010837 poor prognosis Methods 0.000 description 2
230000001323 posttranslational effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
108090000468 progesterone receptors Proteins 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000007634 remodeling Methods 0.000 description 2
201000003825 sigmoid colon cancer Diseases 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
241000894007 species Species 0.000 description 2
230000003393 splenic effect Effects 0.000 description 2
206010041823 squamous cell carcinoma Diseases 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000002381 testicular Effects 0.000 description 2
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
201000002510 thyroid cancer Diseases 0.000 description 2
108091006106 transcriptional activators Proteins 0.000 description 2
102000035160 transmembrane proteins Human genes 0.000 description 2
108091005703 transmembrane proteins Proteins 0.000 description 2
210000003384 transverse colon Anatomy 0.000 description 2
201000010986 transverse colon cancer Diseases 0.000 description 2
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
208000010576 undifferentiated carcinoma Diseases 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
INNTZVXVIZIYBF-PXSLIBMESA-N (2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2R)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid trihydrochloride Chemical compound Cl.Cl.Cl.CCCCCCCCCCCCCCCC(=O)N[C@@H](CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O INNTZVXVIZIYBF-PXSLIBMESA-N 0.000 description 1
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
101710164309 56 kDa type-specific antigen Proteins 0.000 description 1
230000005730 ADP ribosylation Effects 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010069754 Acquired gene mutation Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 description 1
241001481488 Alagoas vesiculovirus Species 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
241001470987 Almendravirus Species 0.000 description 1
102000002572 Alpha-Globulins Human genes 0.000 description 1
108010068307 Alpha-Globulins Proteins 0.000 description 1
241001481502 American bat vesiculovirus Species 0.000 description 1
241000048021 Anterhynchium flavomarginatum micado Species 0.000 description 1
101710145634 Antigen 1 Proteins 0.000 description 1
108700042778 Antimicrobial Peptides Proteins 0.000 description 1
102000044503 Antimicrobial Peptides Human genes 0.000 description 1
241000238421 Arthropoda Species 0.000 description 1
108700020463 BRCA1 Proteins 0.000 description 1
102000036365 BRCA1 Human genes 0.000 description 1
101150072950 BRCA1 gene Proteins 0.000 description 1
101150009389 BZLF1 gene Proteins 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
208000013165 Bowen disease Diseases 0.000 description 1
208000019337 Bowen disease of the skin Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 1
108010079458 CBLB502 Proteins 0.000 description 1
102000049320 CD36 Human genes 0.000 description 1
108010045374 CD36 Antigens Proteins 0.000 description 1
101710120600 Cancer/testis antigen 1 Proteins 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
241001481489 Carajas vesiculovirus Species 0.000 description 1
208000009458 Carcinoma in Situ Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
108090000426 Caspase-1 Proteins 0.000 description 1
102100035904 Caspase-1 Human genes 0.000 description 1
101710090338 Caspase-4 Proteins 0.000 description 1
102100025597 Caspase-4 Human genes 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
241001481494 Chandipura vesiculovirus Species 0.000 description 1
102000002029 Claudin Human genes 0.000 description 1
108050009302 Claudin Proteins 0.000 description 1
241001481490 Cocal vesiculovirus Species 0.000 description 1
206010069729 Collateral circulation Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
241000191855 Curiovirus Species 0.000 description 1
102000005927 Cysteine Proteases Human genes 0.000 description 1
108010005843 Cysteine Proteases Proteins 0.000 description 1
241000712467 Cytorhabdovirus Species 0.000 description 1
230000005778 DNA damage Effects 0.000 description 1
231100000277 DNA damage Toxicity 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
241000255601 Drosophila melanogaster Species 0.000 description 1
238000011510 Elispot assay Methods 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
241001455610 Ephemerovirus Species 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
101710113436 GTPase KRas Proteins 0.000 description 1
108091006109 GTPases Proteins 0.000 description 1
201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
208000031448 Genomic Instability Diseases 0.000 description 1
208000021309 Germ cell tumor Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
241001470875 Hapavirus Species 0.000 description 1
101150046249 Havcr2 gene Proteins 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
108700005087 Homeobox Genes Proteins 0.000 description 1
101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 description 1
101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 1
101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 description 1
101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
101150002416 Igf2 gene Proteins 0.000 description 1
229940125581 ImmunityBio COVID-19 vaccine Drugs 0.000 description 1
101710150706 Inositol monophosphatase 3 Proteins 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
101710126182 Insulin-like growth factor 2 mRNA-binding protein 3 Proteins 0.000 description 1
102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 description 1
108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 description 1
208000005016 Intestinal Neoplasms Diseases 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
241001481491 Isfahan vesiculovirus Species 0.000 description 1
RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
241001481498 Jurona vesiculovirus Species 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000711828 Lyssavirus Species 0.000 description 1
241001481497 Malpais Spring vesiculovirus Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229920000057 Mannan Polymers 0.000 description 1
241001481492 Maraba vesiculovirus Species 0.000 description 1
101710118867 Maurocalcin Proteins 0.000 description 1
238000007476 Maximum Likelihood Methods 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
241000256853 Megascolia flavifrons Species 0.000 description 1
102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
208000002030 Merkel cell carcinoma Diseases 0.000 description 1
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
102000015728 Mucins Human genes 0.000 description 1
108010063954 Mucins Proteins 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
241000234295 Musa Species 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
102000012064 NLR Proteins Human genes 0.000 description 1
241000588650 Neisseria meningitidis Species 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
241001481496 New Jersey vesiculovirus Species 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
241000712466 Nucleorhabdovirus Species 0.000 description 1
108010077991 O-GlcNAc transferase Proteins 0.000 description 1
108010019759 OVA 323-339 Proteins 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
101710116435 Outer membrane protein Proteins 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010013639 Peptidoglycan Proteins 0.000 description 1
102100034763 Peroxiredoxin-2 Human genes 0.000 description 1
241001481493 Piry vesiculovirus Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
102000012515 Protein kinase domains Human genes 0.000 description 1
108050002122 Protein kinase domains Proteins 0.000 description 1
101710109188 Putative inositol monophosphatase 3 Proteins 0.000 description 1
102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
102000034442 RING-type E3 ubiquitin transferases Human genes 0.000 description 1
108030001238 RING-type E3 ubiquitin transferases Proteins 0.000 description 1
102000009572 RNA Polymerase II Human genes 0.000 description 1
108010009460 RNA Polymerase II Proteins 0.000 description 1
102100022491 RNA-binding protein NOB1 Human genes 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
101000910357 Scorpio palmatus Maurocalcin Proteins 0.000 description 1
240000004672 Sigmavirus Species 0.000 description 1
208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
241000439329 Sprivivirus Species 0.000 description 1
208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
101800001271 Surface protein Proteins 0.000 description 1
108090000054 Syndecan-2 Proteins 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
108091005735 TGF-beta receptors Proteins 0.000 description 1
101710192266 Tegument protein VP22 Proteins 0.000 description 1
206010043276 Teratoma Diseases 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
241000982619 Tibrovirus Species 0.000 description 1
108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
102100039387 Toll-like receptor 6 Human genes 0.000 description 1
102100039390 Toll-like receptor 7 Human genes 0.000 description 1
102100033117 Toll-like receptor 9 Human genes 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
241000223104 Trypanosoma Species 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
241000439025 Tupavirus Species 0.000 description 1
108010090473 UDP-N-acetylglucosamine-peptide beta-N-acetylglucosaminyltransferase Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
241001230653 Varicosavirus Species 0.000 description 1
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
101150084041 WT1 gene Proteins 0.000 description 1
101710127857 Wilms tumor protein Proteins 0.000 description 1
102000013814 Wnt Human genes 0.000 description 1
108050003627 Wnt Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
241001481505 Yug Bogdanovac vesiculovirus Species 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
238000007792 addition Methods 0.000 description 1
201000008395 adenosquamous carcinoma Diseases 0.000 description 1
229940021704 adenovirus vaccine Drugs 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
230000005809 anti-tumor immunity Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
108010073160 antigenic peptide Ealpha52-68 Proteins 0.000 description 1
230000005975 antitumor immune response Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000010516 arginylation Effects 0.000 description 1
238000003491 array Methods 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000003373 basosquamous carcinoma Diseases 0.000 description 1
230000006399 behavior Effects 0.000 description 1
102000015736 beta 2-Microglobulin Human genes 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
201000009036 biliary tract cancer Diseases 0.000 description 1
208000020790 biliary tract neoplasm Diseases 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
108010025307 buforin II Proteins 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
208000016576 colorectal neuroendocrine tumor G1 Diseases 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
150000001944 cysteine derivatives Chemical class 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
101150047356 dec-1 gene Proteins 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
108010025838 dectin 1 Proteins 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
229940124447 delivery agent Drugs 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
210000004921 distal colon Anatomy 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
239000012645 endogenous antigen Substances 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
229950009493 entolimod Drugs 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
210000000918 epididymis Anatomy 0.000 description 1
201000010063 epididymitis Diseases 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
210000003495 flagella Anatomy 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
231100000221 frame shift mutation induction Toxicity 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
230000004547 gene signature Effects 0.000 description 1
230000008826 genomic mutation Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000001279 glycosylating effect Effects 0.000 description 1
229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
201000005376 hepatoid adenocarcinoma Diseases 0.000 description 1
238000005734 heterodimerization reaction Methods 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
229940099552 hyaluronan Drugs 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000126 in silico method Methods 0.000 description 1
201000004933 in situ carcinoma Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
201000009019 intestinal benign neoplasm Diseases 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
238000010212 intracellular staining Methods 0.000 description 1
208000020082 intraepithelial neoplasia Diseases 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
208000030776 invasive breast carcinoma Diseases 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
238000001325 log-rank test Methods 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007787 long-term memory Effects 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
102000033952 mRNA binding proteins Human genes 0.000 description 1
108091000373 mRNA binding proteins Proteins 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
208000006178 malignant mesothelioma Diseases 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
108010077372 mast cell degranulating peptide Proteins 0.000 description 1
230000035800 maturation Effects 0.000 description 1
QMBRLNFAEHGOLY-UHFFFAOYSA-N mcd peptide Chemical compound N1C(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)C(C)CC)CSSCC(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(N)=O)NC(=O)C(C(C)CC)NC(=O)C(CCCCN)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C(C)CC)NC(=O)C(CC2N=CN=C2)NC(=O)C2CCCN2C(=O)C(CCCCN)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC2=O)CSSCC1C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC2CC1C=NC=N1 QMBRLNFAEHGOLY-UHFFFAOYSA-N 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
210000003071 memory t lymphocyte Anatomy 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
229940035032 monophosphoryl lipid a Drugs 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
230000007498 myristoylation Effects 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
230000006654 negative regulation of apoptotic process Effects 0.000 description 1
230000018901 negative regulation of programmed cell death Effects 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000000683 nonmetastatic effect Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000008520 organization Effects 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
201000010198 papillary carcinoma Diseases 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
108010043655 penetratin Proteins 0.000 description 1
MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
239000012071 phase Substances 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
238000013081 phylogenetic analysis Methods 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
230000028742 placenta development Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
239000002574 poison Substances 0.000 description 1
229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
108010011110 polyarginine Proteins 0.000 description 1
239000003910 polypeptide antibiotic agent Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
230000013823 prenylation Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000011809 primate model Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000004853 protein function Effects 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
238000001273 protein sequence alignment Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006340 racemization Effects 0.000 description 1
102000016914 ras Proteins Human genes 0.000 description 1
108010014186 ras Proteins Proteins 0.000 description 1
229940124551 recombinant vaccine Drugs 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
201000003858 rectosigmoid cancer Diseases 0.000 description 1
208000028165 rectosigmoid carcinoma Diseases 0.000 description 1
201000003857 rectosigmoid junction cancer Diseases 0.000 description 1
201000001276 rectum malignant melanoma Diseases 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
210000005132 reproductive cell Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
239000002795 scorpion venom Substances 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
238000009589 serological test Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
108091006024 signal transducing proteins Proteins 0.000 description 1
102000034285 signal transducing proteins Human genes 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
230000037439 somatic mutation Effects 0.000 description 1
201000003824 splenic flexure cancer Diseases 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000012353 t test Methods 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
238000001709 templated self-assembly Methods 0.000 description 1
238000010998 test method Methods 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940022511 therapeutic cancer vaccine Drugs 0.000 description 1
208000030829 thyroid gland adenocarcinoma Diseases 0.000 description 1
208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000011222 transcriptome analysis Methods 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
108010062760 transportan Proteins 0.000 description 1
PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
210000002993 trophoblast Anatomy 0.000 description 1
230000037455 tumor specific immune response Effects 0.000 description 1
239000000225 tumor suppressor protein Substances 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
239000002435 venom Substances 0.000 description 1
231100000611 venom Toxicity 0.000 description 1
210000001048 venom Anatomy 0.000 description 1
210000000504 visceral peritoneum Anatomy 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/836—Intestine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20271—Demonstrated in vivo effect
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Toxicology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

JP2023516483A 2020-09-14 2021-09-14 異種プライムブーストワクチン Pending JP2023542297A (ja)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
EP20195872.5		2020-09-14
EP20195872		2020-09-14
EP20210671.2		2020-11-30
EP20210671		2020-11-30
EP21155814.3		2021-02-08
EP21155814		2021-02-08
EP21176373.5		2021-05-27
EP21176373		2021-05-27
PCT/EP2021/075184 WO2022053703A1 (en)	2020-09-14	2021-09-14	Heterologous prime boost vaccine

Publications (1)

Publication Number	Publication Date
JP2023542297A true JP2023542297A (ja)	2023-10-06

Family

ID=77897647

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2023516483A Pending JP2023542297A (ja)	2020-09-14	2021-09-14	異種プライムブーストワクチン

Country Status (18)

Country	Link
US (1)	US20220088162A1 (es)
EP (1)	EP4210734A1 (es)
JP (1)	JP2023542297A (es)
KR (1)	KR20230069956A (es)
CN (1)	CN116348137A (es)
AU (1)	AU2021341521A1 (es)
BR (1)	BR112023001864A2 (es)
CA (1)	CA3188236A1 (es)
CL (1)	CL2023000642A1 (es)
CO (1)	CO2023004596A2 (es)
CR (1)	CR20230155A (es)
DO (1)	DOP2023000053A (es)
EC (1)	ECSP23027542A (es)
IL (1)	IL300060A (es)
MX (1)	MX2023002884A (es)
PE (1)	PE20240492A1 (es)
TW (1)	TW202227126A (es)
WO (1)	WO2022053703A1 (es)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080305120A1 (en)	2004-06-17	2008-12-11	Medimmune, Inc.	Immunogenic Compositions Comprising Hmgb 1 Polypeptides
DE102004034461B4 (de)	2004-07-16	2008-02-07	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
CN109485727A (zh)	2005-05-09	2019-03-19	小野药品工业株式会社	程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
ES2291071B1 (es)	2005-06-13	2009-03-16	Proyecto De Biomedicina Cima, S.L.	Agentes y metodos basados en el uso del dominio eda de la fibronectina.
EP1987839A1 (en)	2007-04-30	2008-11-05	I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale	Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
DK2170959T3 (da)	2007-06-18	2014-01-13	Merck Sharp & Dohme	Antistoffer mod human programmeret dødsreceptor pd-1
EP2044949A1 (en)	2007-10-05	2009-04-08	Immutep	Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
ES2639857T3 (es)	2008-02-11	2017-10-30	Cure Tech Ltd.	Anticuerpos monoclonales para el tratamiento del tumor
US8168757B2 (en)	2008-03-12	2012-05-01	Merck Sharp & Dohme Corp.	PD-1 binding proteins
EP2323685A2 (en)	2008-07-11	2011-05-25	Medizinische Universität Innsbruck	Agonists of nr2f6 for immunosuppression
AR072999A1 (es)	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
DE102008050860A1 (de)	2008-10-08	2010-04-15	Dorothee Von Laer	LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
TWI686405B (zh)	2008-12-09	2020-03-01	建南德克公司	抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
WO2011029980A1 (es)	2009-09-11	2011-03-17	Proyecto De Biomedicina Cima, S.L.	Composiciones terapéuticas para el tratamiento de enfermedades causadas por hpv
RS60033B1 (sr)	2009-11-24	2020-04-30	Medimmune Ltd	Ciljano vezujući agensi usmereni na b7-h1
WO2011101332A1 (en)	2010-02-16	2011-08-25	Proyecto De Biomedicina Cima, S.L.	Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
US8999349B2 (en)	2010-07-27	2015-04-07	The Regents Of The University Of California	HMGB1-derived peptides enhance immune response to antigens
US9555074B2 (en)	2010-10-08	2017-01-31	Regents Of The University Of Minnesota	Annexin II compositions
BR112014012819B1 (pt)	2011-11-28	2022-08-16	Merck Patent Gmbh	Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
SG11201403714TA (en)	2011-12-30	2014-07-30	Halozyme Inc	Ph20 polypeptide variants, formulations and uses thereof
WO2013120073A1 (en)	2012-02-09	2013-08-15	Av Therapeutics, Inc.	Synthetic toll-like receptor-4 (tlr-4) agonist peptides
TWI681969B (zh)	2014-01-23	2020-01-11	美商再生元醫藥公司	針對ｐｄ-１的人類抗體
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20180133327A1 (en)	2015-03-16	2018-05-17	Amal Therapeutics Sa	Cell Penetrating Peptides and Complexes Comprising the Same
EP4378957A2 (en)	2015-07-29	2024-06-05	Novartis AG	Combination therapies comprising antibody molecules to pd-1

2021
- 2021-09-14 PE PE2023001150A patent/PE20240492A1/es unknown
- 2021-09-14 KR KR1020237012084A patent/KR20230069956A/ko unknown
- 2021-09-14 US US17/474,240 patent/US20220088162A1/en active Pending
- 2021-09-14 CA CA3188236A patent/CA3188236A1/en active Pending
- 2021-09-14 WO PCT/EP2021/075184 patent/WO2022053703A1/en active Application Filing
- 2021-09-14 JP JP2023516483A patent/JP2023542297A/ja active Pending
- 2021-09-14 MX MX2023002884A patent/MX2023002884A/es unknown
- 2021-09-14 IL IL300060A patent/IL300060A/en unknown
- 2021-09-14 AU AU2021341521A patent/AU2021341521A1/en active Pending
- 2021-09-14 CR CR20230155A patent/CR20230155A/es unknown
- 2021-09-14 CN CN202180062772.6A patent/CN116348137A/zh active Pending
- 2021-09-14 EP EP21773815.2A patent/EP4210734A1/en active Pending
- 2021-09-14 BR BR112023001864A patent/BR112023001864A2/pt unknown
- 2021-09-14 TW TW110134259A patent/TW202227126A/zh unknown
2023
- 2023-03-07 CL CL2023000642A patent/CL2023000642A1/es unknown
- 2023-03-14 DO DO2023000053A patent/DOP2023000053A/es unknown
- 2023-04-13 CO CONC2023/0004596A patent/CO2023004596A2/es unknown
- 2023-04-14 EC ECSENADI202327542A patent/ECSP23027542A/es unknown

Also Published As

Publication number	Publication date
CR20230155A (es)	2023-06-27
AU2021341521A2 (en)	2023-04-13
BR112023001864A2 (pt)	2023-03-28
WO2022053703A1 (en)	2022-03-17
DOP2023000053A (es)	2023-08-15
MX2023002884A (es)	2023-03-31
EP4210734A1 (en)	2023-07-19
CN116348137A (zh)	2023-06-27
TW202227126A (zh)	2022-07-16
US20220088162A1 (en)	2022-03-24
PE20240492A1 (es)	2024-03-15
KR20230069956A (ko)	2023-05-19
AU2021341521A1 (en)	2023-03-30
CO2023004596A2 (es)	2023-07-10
CL2023000642A1 (es)	2023-10-30
ECSP23027542A (es)	2023-07-31
IL300060A (en)	2023-03-01
CA3188236A1 (en)	2022-03-17

Legal Events

Date

Code

Title

Description

2023-12-26

RD02

Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20231226

2024-01-19

RD04

Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231227

Publication	Publication Date	Title
JP7190528B2 (ja)	2022-12-15	神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体
KR102308798B1 (ko)	2021-10-05	다양한 암의 면역요법 치료에서의 사용을 위한 펩티드, 펩티드의 조합 및 골격
Hartman et al.	2011	Increasing vaccine potency through exosome antigen targeting
JP7346291B2 (ja)	2023-09-19	癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体
EP2403935B1 (en)	2017-05-10	Compositions comprising angiogenic factors and methods of use thereof
JP7232825B2 (ja)	2023-03-03	腫瘍関連抗原エピトープの微生物叢（ｍｉｃｒｏｂｉｏｔａ）配列変異体
JP2019510488A (ja)	2019-04-18	抗腫瘍免疫を誘導するための、腫瘍関連抗原の複数のエピトープを発現するウイルスベクター
JP2023506381A (ja)	2023-02-16	細胞外小胞をプログラムするための組換えポリペプチド
US20240075117A1 (en)	2024-03-07	Microbiota sequence variants of tumor-related antigenic epitopes
Yang et al.	2019	Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo
Rodriguez-Garcia et al.	2017	T-cell target antigens across major gynecologic cancers
CN111655278A (zh)	2020-09-11	免疫治疗性癌症控制中的混合谱系激酶结构域样蛋白
JP2022553192A (ja)	2022-12-22	癌ワクチン
AU2015233542B2 (en)	2020-01-16	A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
EP4045150A1 (en)	2022-08-24	Immunogenic compounds for treatment of adrenal cancer
Moeini et al.	2017	Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine
JP2023503857A (ja)	2023-02-01	がんを治療するための腫瘍内及び／または静脈内投与用組み換えｍｖａウイルス
JP2021532791A (ja)	2021-12-02	がんの予防または治療方法において使用するためのがん／精巣抗原をコードするウイルスベクター
JP2023542297A (ja)	2023-10-06	異種プライムブーストワクチン
Chaganty et al.	2022	Redirecting host preexisting influenza A virus immunity for cancer immunotherapy
CN113795272A (zh)	2021-12-14	涉及car工程化的t细胞和细胞因子的治疗
Josi et al.	2024	A tetravalent nanovaccine that inhibits growth of HPV-associated head and neck carcinoma via dendritic and T cell activation
KR20230035576A (ko)	2023-03-14	Hpv 양성 암 치료용 rna
TW202346363A (zh)	2023-12-01	腫瘤抗原、包含所述腫瘤抗原的化合物及其用途
Chen	2013	HER2/neu-specific Breast Cancer Vaccine